Federal Circuit Tarceva decision is good news for oncology patent owners
Appellate court overturns PTAB invalidation, citing uncertainties of R&D in the lucrative cancer space, as well as lack of data in prior art
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.